Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Among the adverse event reports associated with propranolol treatment for IH, the most frequently reported concomitant medications were timolol (9.25%), cholecalciferol (5.20%), prednisolone (4.05%), and furosemide (4.05%) (Table 3).Top six concomitant medications in the treatment of IH with propranololPropranolol(n, %)IndicationInfantile hemangioma173, (100)Concomitant medicationTimolol16, (9.25)Cholecalciferol9, (5.20)Prednisolone7, (4.05)Furosemide7, (4.05)Incremin6, (3.47)Ranitidine6, (3.47)Spironolactone6, (3.47)
Source: Concomitant medication analysis in propranolol-treated IH cases. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database
Study design awaiting verification · Orphanet Journal of Rare Diseases · 2026
Original publication title
Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Propranolol, a non-selective β-adrenergic receptor blocker, is the first FDA-approved orphan drug for the treatment of infantile hemangioma (IH). While it has demonstrated substantial therapeutic benefits, the safety profile of propranolol in infants remains insufficiently characterized, particularly in real-world settings.
Source: ObjectiveAbstract: What methods does the paper describe?
A retrospective pharmacovigilance analysis of FAERS reports from Q1 2015 to Q4 2024 was conducted, applying four signal detection algorithms (ROR, PRR, BCPNN, MGPS) to identify disproportional AE signals related to propranolol in IH.
Source: MethodsAbstract: Results
A total of 1615 AE reports were included. Signal detection identified events across 20 System Organ Classes (SOCs), with vascular, psychiatric, and metabolism and nutrition disorders being most prominent. At the Preferred Term (PT) level, the most frequently reported AEs were sleep disorder (n = 149, ROR = 32.67), peripheral coldness (n = 87, ROR = 108.73), and hypoglycaemia (n = 62, ROR = 22.95), which were pharmacologically plausible and clinically relevant.
Source: ResultsAbstract: Conclusions
This study identified safety signals associated with propranolol in infants with IH, highlighting risks across organ systems. These findings support the need for vigilant monitoring, individualized risk assessment, and refinement of labeling recommendations to optimize safety in this vulnerable population.
Source: ConclusionsAuthors’ abstract
Objective
Propranolol, a non-selective β-adrenergic receptor blocker, is the first FDA-approved orphan drug for the treatment of infantile hemangioma (IH). While it has demonstrated substantial therapeutic benefits, the safety profile of propranolol in infants remains insufficiently characterized, particularly in real-world settings.
Methods
A retrospective pharmacovigilance analysis of FAERS reports from Q1 2015 to Q4 2024 was conducted, applying four signal detection algorithms (ROR, PRR, BCPNN, MGPS) to identify disproportional AE signals related to propranolol in IH.
Results
A total of 1615 AE reports were included. Signal detection identified events across 20 System Organ Classes (SOCs), with vascular, psychiatric, and metabolism and nutrition disorders being most prominent. At the Preferred Term (PT) level, the most frequently reported AEs were sleep disorder (n = 149, ROR = 32.67), peripheral coldness (n = 87, ROR = 108.73), and hypoglycaemia (n = 62, ROR = 22.95), which were pharmacologically plausible and clinically relevant.
Conclusions
This study identified safety signals associated with propranolol in infants with IH, highlighting risks across organ systems. These findings support the need for vigilant monitoring, individualized risk assessment, and refinement of labeling recommendations to optimize safety in this vulnerable population.
Supplementary information
The online version contains supplementary material available at 10.1186/s13023-026-04331-4.
Publication and source details
Original title: Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database
Xuanjia Li; Xingyu Zhao; Chengzhe Yang; Anwei Chen
Orphanet Journal of Rare Diseases · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:32:57.195126+00:00
DOI: 10.1186/s13023-026-04331-4 · PMC13154883